BRAIN IPO: End of the stabilisation period and exercise of the Greenshoe Option
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Miscellaneous/IPO
2016-03-10 / 11:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
BRAIN IPO: End of the stabilisation period and exercise of the Greenshoe
Option
Zwingenberg, March 10, 2016: B.R.A.I.N. Biotechnology Research And
Information Network AG ("BRAIN AG"; ISIN DE0005203947 / WKN 520394) was
informed by ODDO SEYDLER BANK AG that the stabilisation period in
connection with the initial public offering ended yesterday, as planned. On
the same day, ODDO SEYDLER exercised the Greenshoe Option in the amount of
108,054 shares, with the effect that all shares, which had been
over-allotted at the IPO, are now fully placed. The over-allotment shares
were provided from the holdings of MP Beteiligungs-GmbH by way of a share
loan. With the exercise of the Greenshoe Option, the MP Beteiligungs-GmbH
holdings of BRAIN shares decrease to 39.2%, resulting in a free float of
currently 22.0%.
In connection with the BRAIN IPO, ODDO SEYDLER BANK AG was entitled, as
stabilisation manager, to carry out measures to support the stock market
price of BRAIN shares (stabilisation measures) until the thirtieth calendar
day after the first day of trading of the shares, which was on February 9,
2016. Stabilisation measures were taken only to a small extent on February
9, 2016, the first day of the stabilisation period. They took place within
a price range of 8.90 Euros and 9.00 Euros. The respective notice pursuant
to article 9(3) of Commission Regulation (EC) No 2273/2003 of December 22,
2003 can be downloaded from the website of BRAIN AG at
www.brain-biotech.de/en/investor-relations/ipo.
"The outcome of the stabilisation period and the positive share price
development since the start of trading show that our shares have been
sustainably placed in the capital market. Also, this confirms the trust
that our investors place in the long-term growth potential of BRAIN AG and
the field of bioeconomy in general. Our IPO project is now successfully
concluded with the exercise of the Greenshoe Option", says Dr Jürgen Eck,
CEO of BRAIN AG. "This motivates us even more to take advantage of the
tremendous potential of the bioeconomy while we continue to drive forward
and expand our industrialisation strategy."
+++ENDS+++
About BRAIN
BRAIN is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN
identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this "Toolbox of Nature" are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars - "BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive - collaboration business
with industrial partners. The second pillar "BioIndustrial" comprises the
development and commercialisation of BRAIN's own products and active
product components. Further information is available at
www.brain-biotech.de/en
Contact:
B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
Tel.: +49-6251-9331-0
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de
Disclaimer
This publication does not constitute an offer to sell, or the solicitation
of an offer to buy or subscribe for any securities. The public offer of
shares of B.R.A.I.N. Biotechnology Research And Information Network AG is
already concluded. This release is not for publication, release or
distribution in the United States of America, Canada, Australia or Japan.
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. There are numerous factors
which could influence the future performance by and future developments at
BRAIN AG and the BRAIN group of companies. Such factors include, but are
not limited to, changes in the general economic and competitive
environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations,
in particular with respect to tax laws and regulations, and other factors.
BRAIN AG does not undertake any obligation to update or revise any
forward-looking statements.
---------------------------------------------------------------------------
2016-03-10 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.de
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service